Primary endpoint met for SGLT2i in HF outcomes trial

Results from the DAPA-HF trial were announced: treatment with the SGLT2 inhibitor dapagliflozin resulted in reduction of CV death or worsening of heart failure (HF) (defined as hospitalization or an urgent HF visit) compared to placebo in a population of HF patients with reduced ejection fraction (HFrEF) with and without type 2 diabetes.

The safety profile was consistent with that in previous studies.

DAPA-HF is the first HF outcomes trial with an SGLT2 inhibitor evaluating the effect in patients with HFrEF on top of standard of care (which includes ACEi, ARBs, beta-blockers, MRAs and neprilysin inhibitors) in patients with and without type 2 diabetes. DAPA-HF is an international, multicenter, parallel group, randomized, double-blind trial in HFrEF patients.

Full results will be submitted for presentation at a forthcoming medical meeting.

The DELIVER and DETERMINE trials are examining the effect of dapagliflozin in HF patient with preserved ejection fraction (HFpEF) and HFrEF and HFpEF, respectively.

Source: press release AstraZeneca , August 20, 2019